Yan Leyfman, MD, Hematology-Oncology Fellow at NewYork-Presbyterian Brooklyn Methodist Hospital and Executive Director of MedNews Week, shared on LinkedIn:
“AI didn’t wait for oncology to build the rules. It simply arrived.
Today, clinicians are increasingly using AI to interpret complex information, navigate treatment options and clinical trials, and support decisions that are becoming more personalized – and more complicated.
But that raises an important question: Who is responsible when AI gets it wrong?
That question became the foundation for our new article on AI governance in precision oncology.
In our survey of 52 U.S. oncology clinicians, 83% reported independently using AI on personal platforms, while 71% reported no institutional AI governance policy and 77% were operating without institutional oversight.
Perhaps most striking was what we call the ‘verification paradox.’ Nearly everyone intended to verify AI-generated recommendations- yet 23% would still have followed an intentionally embedded dosing error.
That matters even more as we move into increasingly complex areas of oncology: CAR-T therapy, bispecific antibodies, molecular classification, MRD monitoring, and highly individualized treatment decisions. These are areas where AI has enormous potential, but where confidently incorrect recommendations can also carry serious consequences.
Our conclusion is simple:
The oncologist of the AI era cannot simply be an AI user. We must become AI curators.
That means selecting the right tools, understanding their limitations, validating their performance, recognizing when they fail, and ultimately maintaining human accountability for the patient in front of us.
Technology will continue to evolve. Clinical accountability cannot.
I’m incredibly grateful to Dr. Arturo LoAIza-Bonilla MD for his tremendous mentorship and for continually challenging me to think more deeply about how we responsibly bring emerging technologies into cancer care.
I also sincerely thank the AIPO Journal, Dr. Douglas Flora, LSSBB, Dr. Nikhil Thaker, and Dr. Sanjay Juneja, for providing a platform for these important conversations at the intersection of AI, innovation, and oncology.
The future of oncology will undoubtedly involve AI. The question is how we ensure that we remain worthy stewards of it.”
Title: Governing What We Cannot Yet Verify: The Verification Paradox and Responsible AI Implementation in Precision Oncology
Authors: Yan Leyfman, Arturo Loaiza-Bonilla
Other articles about AI on OncoDaily.